About M&L Healthcare
M&L Healthcare is a venture capital firm founded in 2019. It is primarily based out of Singapore, Singapore. As of Apr 2026, M&L Healthcare has invested in 13 companies. It primarily invests in Series C round in France based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series C round of Endovascular Engineering Overall, M&L Healthcare portfolio has seen 1 acquisition, namely Limflow. A lot of funds co-invest with M&L Healthcare, with names like Bpifrance sharing a substantial percentage of its portfolio. M&L Healthcare has team of 15 people including 6 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 1 more
Portfolio Acquisitions
Deals in last 12 months
M&L Healthcare's List of Top Investments
M&L Healthcare has a portfolio of 13 companies. Their most notable investments are in Pedra and TISSIUM.Their portfolio spans across France, United States, Singapore and 2 more locations. They have invested in Life Sciences, High Tech, HealthTech, across Series A, Series B and 1 more. Here is the list of top investments by M&L Healthcare:
1. TISSIUM
Developer of vascular sealant for open vascular surgery. The company has developed biomorphic and programmable polymers for natural tissue healing. The flagship product, SETALIUM is a biocompatible, biodegradable, and on-demand activated sealant, designed to help achieve hemostasis during open vascular surgery.
Key facts about TISSIUM
- Founded Year: 2013
- Location: Paris (France)
- Stage: Series D
- Total Funding till date: $190M
- Employee Count: 145 as on Aug 31, 2026
- Investors: BNP Paribas, Exor and 17 Others
- Latest Funding Round: Series D, Jun 24, 2026, $*****
- Highlight: Editors' Pick
2. CorWave
Developer of implantable heart assist pumps for advanced heart failure. These medical devices utilize wave membrane technology to provide pulsatile blood flow for patients suffering from cardiac conditions. The technology functions as a left ventricular assist device to support heart function.
Key facts about CorWave
- Founded Year: 2012
- Location: Clichy (France)
- Annual Revenue: €10M - €50M as on Dec 31, 2023
- Stage: Series C
- Total Funding till date: $92.8M
- Employee Count: 122 as on Aug 31, 2026
- Investors: Exor, Novo Holdings and 13 Others
- Latest Funding Round: Series C, Jun 20, 2023, $*****
- Highlight: Editors' Pick
Developer of a device for removal of vascular blockages. The company is developing a Lesion Preparation balloon designed to enable more effective removal of blockages in blood vessels and to increase drug uptake when used along with a Drug-Coated Balloon. Their technology has applications in the treatment of Peripheral arterial disease.
Key facts about Cagent Vascular
- Founded Year: 2014
- Location: Wayne (United States)
- Stage: Series D
- Total Funding till date: $110M
- Employee Count: 105 as on Aug 31, 2026
- Investors: Sectoral, Trinity Capital and 9 Others
- Latest Funding Round: Series D, May 18, 2026, $*****
- Highlight: Editors' Pick
4. Corflow
Developer of diagnostic and therapeutic solutions for microvascular obstruction. It offers CoFI System that fits into the PCI workflow using the existing guide catheter and wire access for restoring healthy microvascular blood flow in the human body.
Key facts about Corflow
- Founded Year: 2016
- Location: Baar (Switzerland)
- Stage: Series B
- Total Funding till date: $51.3M
- Employee Count: 43 as on Sep 30, 2026
- Investors: Korys, Wellington Partners Venture Capital and 10 Others
- Latest Funding Round: Series B, Sep 10, 2024, $*****
- Highlight: Editors' Pick
Provider of mechanical thrombectomy technologies to treat venous thromboembolism. It offers Hēlo Thrombectomy System designed to remove clots efficiently using a dual-action mechanism. It combines aspiration and mechanical clot disruption with a small profile catheter that expands for high-performance clot engagement.
Key facts about Endovascular Engineering
- Founded Year: 2019
- Location: Menlo Park (United States)
- Stage: Series C
- Total Funding till date: $122M
- Investors: Gilde Healthcare, Norwest and 7 Others
- Latest Funding Round: Series C, Apr 07, 2026, $*****
- Highlight: Editors' Pick
M&L Healthcare's Year-on-Year Investment Trends
M&L Healthcare has invested in 13 companies over the last 7 years, with an average of 1 new investment annually in the last 5 years. In 2025, it made 3 investments, while as of Apr 2026, it has made 1 investment in this year. Its most recent first time investment was in SafeHeal and most recent follow-on round was in Endovascular Engineering.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 1 | 1 |
2025 | 2 | 1 | 3 |
2024 | 3 | 0 | 3 |
2023 | 0 | 0 | 0 |
2022 | 0 | 0 | 0 |
2021 | 0 | 0 | 0 |
2020 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
M&L Healthcare's Investments by Stage
M&L Healthcare has made 3 investments in Series A stage with an average round size of $10M, 3 investments in Series B stage with an average round size of $44.5M and 1 investment in Series C stage with an average round size of $39.9M.Stage of entry | No. of Investments |
|---|---|
Series A | 3 |
Series B | 3 |
Series C | 1 |
Note: We have considered here, only first round of investments
M&L Healthcare's Investments by Sector
M&L Healthcare has a diverse portfolio, with companies operating in the Life Sciences and HealthTech. Notably, it has invested in 13 Enterprise (B2B) companies, 13 Tech companies, 10 Tech hardware companies and 1 company focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 7 |
HealthTech | 1 |
Note: We have considered here, only first round of investments
M&L Healthcare's Investments by Geography
M&L Healthcare has made most investments in France (3), followed by United States where it has made 2 investments.Country | No. of Investments |
|---|---|
France | 3 |
United States | 2 |
Singapore | 1 |
Switzerland | 1 |
Note: We have considered here, only first round of investments
M&L Healthcare's recent investments
M&L Healthcare has made 1 investments in 2026 so far - Endovascular Engineering.Here are the most recent investments by M&L Healthcare:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Apr 07, 2026 | United States | Series C | 2023 | [+5] | |
Sep 10, 2025 | France | Series C | 8044 | [+4] | |
Apr 30, 2025 | France | Series C | 2298 | [+2] | |
Feb 18, 2025 | United States | Series B | 7922 | [+3] | |
Dec 16, 2024 | United States | Series A | 9672 |
Acquired companies in M&L Healthcare's Portfolio
1 company from M&L Healthcare's portfolio has been acquired. The most recent acquisition was Limflow in Nov 2023 by Inari Medical for $*****.Here are M&L Healthcare's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Nov 01, 2023 | - | - | 1640 |
Team profile of M&L Healthcare
M&L Healthcare has a team of 15 members including 6 Partners and 6 Principals located in Singapore, Australia and 2 more locations. M&L Healthcare's team does not sit on the board of any company as of now.Here is a list of top team members in M&L Healthcare:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Amsterdam | - | - | |
Partner | - | - | - | |
Partner | - | - | - | |
Partner | - | - | - | |
Partner | - | - | - | |
Partner | - | - | - | |
Principal | Singapore | - | - | |
Principal | Australia | - | - | |
Principal | Palmerston North | - | - | |
Principal | - | - | - | |
Principal | - | - | - |
Co-investors of M&L Healthcare
Over the past 7 years, 41 investors have co-invested in M&L Healthcare's portfolio companies. This includes only funds.
- Invested before M&L Healthcare: Cordis, Sante and 5 others have invested in rounds before M&L Healthcare. There is 1 company where Cordis has invested before M&L Healthcare and 1 company where Sante has invested before M&L Healthcare.
- Top Co-investors of M&L Healthcare: 23 investors entered a company along with M&L Healthcare. These include investors like Bpifrance (2 companies).
- Invested after M&L Healthcare: A total of 11 investors have invested in M&L Healthcare's portfolio after their investments. Top Investors include Cathay Capital (1 company), BNP Paribas (1 company) and ISALT (1 company).
Recent News related to M&L Healthcare
•
•
SafeHeal Closes €35M Series C Equity FinancingFinSMEs•May 01, 2025•SafeHeal, Gideon Strategic Partners, M&L Healthcare, Sofinnova Partners
•
Endovascular Engineering Raises $42 Million in Series B Financing to Advance the Treatment of Pulmonary EmbolismPR Newswire•Feb 18, 2025•Endovascular Engineering, 415 CAPITAL, S3 Ventures, M&L Healthcare and 3 others
•
FastWave Medical: $19 Million Raised To Develop Intravascular Lithotripsy SystemsPulse 2.0•Dec 25, 2024•FastWave Medical, Epic Venture Partners, M&L Healthcare
•
•
CorFlow Therapeutics AG Completes €44 Million Series B Financing to Support the Advancement of a Novel Diagnostic and Drug Delivery Platform for Microvascular Obstruction (MVO) in Heart Attack PatientsFinancial Post•Sep 10, 2024•Corflow, Broadview Ventures, Panakes Partners, 415 CAPITAL and 9 others
•
HEPTA Medical Secures €5.7 Million Series A, Led by BPI France to Advance Minimally Invasive Lung Cancer TreatmentBusiness Wire•Sep 04, 2024•HEPTA Medical, Bpifrance, M&L Healthcare, Cléry
•
CorWave raises $40m in funding for breakthrough heart pumpMassDevice•Jan 06, 2021•CorWave, Bpifrance, Novo Holdings, Novoseeds and 7 others
•
Pedra Technology Secures $4.7M in Series A FundingFinSMEs•Sep 22, 2020•Pedra, Seeds Capital, M&L Healthcare
